Kindred Biosciences has entered into an agreement with Vaxart for the manufacture of Vaxart’s oral vaccine candidate for COVID-19.   “We are proud to be contributing toward the effort to develop a COVID-19 vaccine. We look forward to working with Vaxart to bring this innovative technology to patients as quickly as possible,” said Richard Chin, chief executive officer, Kindred Biosciences. “This marks an important step in the development of our contract manufacturing busin...